United Therapeutics Gestion
Gestion contrôle des critères 2/4
Le PDG United Therapeutics est Martine Rothblatt, nommé en Jan1996, a un mandat de 28.83 ans. La rémunération annuelle totale est $ 16.96M, composée du salaire de 8.7% et des bonus 91.3%, y compris les actions et options de la société. détient directement 1.49% des actions de la société, d'une valeur de $ 251.39M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 15.6 ans et 22.2 ans.
Informations clés
Martine Rothblatt
Directeur général
US$17.0m
Rémunération totale
| Pourcentage du salaire du PDG | 8.7% |
| Durée du mandat du directeur général | 28.8yrs |
| Propriété du PDG | 1.5% |
| Durée moyenne d'occupation des postes de direction | 15.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 22.2yrs |
Mises à jour récentes de la gestion
Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Rémunération vs marché: La rémunération totale de Martine ($USD 16.96M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.50M ).
Rémunération et revenus: La rémunération de Martine a augmenté de plus de 20 % au cours de l'année écoulée.
PDG
Martine Rothblatt (69 yo)
28.8yrs
Titularisation
US$16,958,057
Compensation
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 251.4m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 971.1k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.018% $ 3.0m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.8m | |
| Head of Investor Relations | no data | pas de données | pas de données | |
| Associate Vice President of Human Resources | no data | pas de données | pas de données | |
| Senior Vice President of Strategic Operations & Logistics | no data | pas de données | pas de données | |
| Executive VP of Technical Operations | 15.6yrs | pas de données | pas de données | |
| Executive Vice President of Product Development & Xenotransplantation | no data | pas de données | pas de données | |
| Senior VP & Chief Medical Officer | no data | pas de données | pas de données |
15.6yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de UTHR est chevronnée et expérimentée (15.6 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 251.4m | |
| Member of the Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.6m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.9m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 659.8k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 754.0k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0082% $ 1.4m | |
| Member of the Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.5m | |
| Member of the Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 9.4yrs | US$488.66k | 0.013% $ 2.1m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.6m |
22.2yrs
Durée moyenne de l'emploi
76yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la UTHR est chevronné et expérimenté ( 22.2 années d'ancienneté moyenne).